Literature DB >> 12699689

Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells.

Matthew Galfione1, Weiping Luo, Jeri Kim, David Hawke, Ryuji Kobayashi, Carmen Clapp, Li-Yuan Yu-Lee, Sue-Hwa Lin.   

Abstract

The 16-kDa fragment of prolactin (16-kDa PRL), derived from proteolytic cleavage of 23-kDa PRL, was shown to have antiangiogenic activity. Previous studies have shown that recombinant 16-kDa PRL produced from bacteria often contained endotoxins, which are cytotoxic to endothelial cells, and varied in its biological activity due to changes in its refolding from inclusion bodies. These problems limited the use of recombinant 16-kDa PRL. To improve the generation of recombinant 16-kDa PRL, we expressed 16-kDa PRL in Sf9 insect cells using a baculoviral expression system. The signal sequence of the human PRL gene and codons for seven histidines were added to the N- and C-termini, respectively, of the 16-kDa PRL cDNA construct. Recombinant 16-kDa PRL was detected in both the cell pellet and the medium. About 0.28 mg purified protein was isolated from the cell pellet of 4 x 10(7) infected cells using nickel affinity chromatography. Sixteen kilodalton PRL was posttranslationally modified with apparent molecular weights of 16 and 18 kDa on SDS-PAGE. The level of 18-kDa protein was significantly reduced after digestion with peptidyl-N-glycosidase, suggesting that the heterogeneity was due to glycosylation of 16-kDa PRL. N-terminal sequence analysis confirmed the fact that both proteins were human 16-kDa PRL and the signal sequences were cleaved at the same position as that of human PRL. Consistent with its role as an angiogenesis inhibitor, purified recombinant 16-kDa PRL inhibits the proliferation of endothelial cells with a potency similar to that previously reported for the protein generated in Escherichia coli. This 16-kDa PRL expressed in Sf9 cells is a useful reagent for functional studies and for the purification and identification of its receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699689     DOI: 10.1016/s1046-5928(02)00639-3

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  12 in total

1.  Fast and easy protocol for the purification of recombinant S-layer protein for synthetic biology applications.

Authors:  Julie E Norville; Deborah F Kelly; Thomas F Knight; Angela M Belcher; Thomas Walz
Journal:  Biotechnol J       Date:  2011-06-17       Impact factor: 4.677

Review 2.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

3.  Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation.

Authors:  Gabriela Vazquez Rodriguez; Carmen Gonzalez; Antonio De Leon Rodriguez
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

4.  Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.

Authors:  Celina García; Jorge Aranda; Edith Arnold; Stéphanie Thébault; Yazmín Macotela; Fernando López-Casillas; Valentín Mendoza; Hugo Quiroz-Mercado; Hebert Luis Hernández-Montiel; Sue-Hwa Lin; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

5.  Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis.

Authors:  Yu-Chen Lee; Mehmet Asim Bilen; Guoyu Yu; Song-Chang Lin; Chih-Fen Huang; Angelica Ortiz; Hyojin Cho; Jian H Song; Robert L Satcher; Jian Kuang; Gary E Gallick; Li-Yuan Yu-Lee; Wilber Huang; Sue-Hwa Lin
Journal:  Mol Cancer Res       Date:  2013-08-02       Impact factor: 5.852

6.  Requirement of phosphorylatable endothelial nitric oxide synthase at Ser-1177 for vasoinhibin-mediated inhibition of endothelial cell migration and proliferation in vitro.

Authors:  Celina García; Rosa Elvira Nuñez-Anita; Stéphanie Thebault; David Arredondo Zamarripa; Michael C Jeziorsky; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  Endocrine       Date:  2013-05-03       Impact factor: 3.633

7.  N-terminal prolactin-derived fragments, vasoinhibins, are proapoptoptic and antiproliferative in the anterior pituitary.

Authors:  Jimena Ferraris; Daniela Betiana Radl; Sandra Zárate; Gabriela Jaita; Guadalupe Eijo; Verónica Zaldivar; Carmen Clapp; Adriana Seilicovich; Daniel Pisera
Journal:  PLoS One       Date:  2011-07-07       Impact factor: 3.240

8.  Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer.

Authors:  Pratima Nangia-Makker; Yi Wang; Tirza Raz; Larry Tait; Vitaly Balan; Victor Hogan; Avraham Raz
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.316

9.  Vasoinhibins regulate the inner and outer blood-retinal barrier and limit retinal oxidative stress.

Authors:  David Arredondo Zamarripa; Nundehui Díaz-Lezama; Rodrigo Meléndez García; Jesús Chávez Balderas; Norma Adán; Maria G Ledesma-Colunga; Edith Arnold; Carmen Clapp; Stéphanie Thebault
Journal:  Front Cell Neurosci       Date:  2014-10-20       Impact factor: 5.505

10.  Dual contribution of TRPV4 antagonism in the regulatory effect of vasoinhibins on blood-retinal barrier permeability: diabetic milieu makes a difference.

Authors:  David Arredondo Zamarripa; Ramsés Noguez Imm; Ana María Bautista Cortés; Osvaldo Vázquez Ruíz; Michela Bernardini; Alessandra Fiorio Pla; Dimitra Gkika; Natalia Prevarskaya; Fernando López-Casillas; Wolfgang Liedtke; Carmen Clapp; Stéphanie Thébault
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.